AVEO Pharmaceuticals — Investor Presentation (October 2019)
34 slides from AVEO Pharmaceuticals's investor presentation, Oct 3, 2019
Slide 1: AVEO Overview October 2019
AVEO Overview October 2019 Exhibit 99 .1
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained
Slide 3: AVEO Oncology: Strategy for Value Creation
AVEO Oncology: Strategy for Value Creation Value Enhancing Partnerships Deep Pipeline Addressing Significant Unmet Needs Multiple oncology and non-oncology pipeline opportunities FOTIVDA® (tivozanib) – IO Combinations (RCC, HCC, other) Selective VEGFR TKI has potential to enable unique tolerability
Slide 4: Pipeline overview
Clinical Preclinical Phase 1 Phase 2 Phase 3 Regulatory Filing Marketed Partner Tivozanib (RCC) VEGFR 123 TKI Tivozanib (HCC) VEGFR 123 TKI Ficlatuzumab HGF MAb AV-203 (CAN017) ERBB3 MAb Multiple Potential Opportunities for Value Creation TIVO-1 (Phase 3 Registration Study in 1st Line RCC) TIVO-3 (P
Slide 5: Financial Highlights
Financial Highlights Cash on hand to fund planned operations into 3Q 2021* $40.2M in cash, cash equivalents, and marketable securities as of 2Q 2019 $25.0M upfront payment from Kyowa Kirin received in 3Q 2019 Kyowa Kirin buy back of tivozanib non-oncology rights: $25.0M upfront payment Waiver of the
Slide 6: FOTIVDA (tivozanib) TIVO-3 Pivotal Phase 3 Study
FOTIVDA® (tivozanib) TIVO-3 Pivotal Phase 3 Study
Slide 7: Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor
Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor Potent, selective inhibitor of VEGFRs 1, 2 and 3 with a long half-life that is designed to optimize blockade while minimizing off-target toxicities1,2 1 Nakamura K et al. Cancer Res 2006;66:9134–9142. 2 Eskens FA et al. Clin Cancer Res 2011;17:71
Slide 8: TIVO-3: Study Design
TIVO-3: Study Design N = 350 F Recurrent/metastatic RCC Failed at least two prior regimens including VEGFR-TKI Stratified by prior regimen (TKI-TKI; TKI-PD1; TKI-Other) ECOG PS 0 or 1 RANDOMIZE 1:1 tivozanib sorafenib 1O: PFS 2O: OS, ORR, DoR, Safety and Tolerability for ITT 60% 3rd line patients, 4
Slide 9: TIVO-3: Superior PFS and ORR
| TIVO-3: Superior PFS and ORR ‘Median PFS, mo (95% Cl) Tivozanib 5.6 (5.3, 7.3) Sorafenib 3.9 (3.7,5.6) HR, 0.73 (95% Cl: 0.56, 0.94) P=0,0165 2yr PFS e Survival Probability | 18% * Statistically significant benefit in ORR, p=0.02 * Durable responses with tivozanib: + 55% remaining in response past
Slide 10: Progression-Free Survival – Key Subgroups
Progression-Free Survival – Key Subgroups* *Final analysis, as of Oct 4, 2018 Tivozanib Sorafenib Tivozanib Sorafenib Porta et al. ASCO 2019
Slide 11: Treatment-Related Adverse Events
Treatment-Related Adverse Events* (≥20% frequency in either arm) Tivozanib (N=173)^ Sorafenib (N=170)^ Preferred Term All Grades % Grade 3/4 % All Grades % Grade 3/4 % Treatment Related AEs 84 44 94 55 Hypertension 36 20 25 14 Diarrhea 33 2 50 9 Fatigue 29 4 19 5 Decreased Appetite 26 4 21 2 Dysphon
Slide 12: Tolerability Results
Tivozanib (N=173)^ Sorafenib (N=170)^ Mean Number of Cycles Initiated 10.3 6.3 AEs Leading to Dose Reductions (%) 24 38 AEs Leading to Dose Interruption (%) 48 63 Treatment Related SAEs (%) 11 10 Treatment Related Deaths (%) 0 0 Deaths within 30 days of Tx (N) 15 12 Exposure Adj Deaths per Month of
Slide 13: Patients Benefiting Most from Tivozanib Underrepresented in Preliminary OS Analysis
Patients Benefiting Most from Tivozanib Were Underrepresented in Preliminary OS Analysis 2yr PFS 18% 5% 28% 1yr PFS 11% TIVO-3 PFS Curve (ITT) 72% of OS events in preliminary analysis from patients with <4 months of PFS (Oct 4, 2018 Data Cut)
Slide 14: Secondary Endpoint – Overall Survival
Secondary Endpoint – Overall Survival Initial OS Analysis (Oct 4, 2018): HR* >1.00 Analysis based on 183 OS events Prespecified OS Analysis Update (Aug 15, 2019): HR*=0.99 Analysis based on 227 OS events 95% CI: 0.76-1.29; p=0.95 44 additional events since Oct 4, 2018 data cut 16 tivozanib events an
Slide 15: TIVO-3 Conclusions
TIVO-3 Conclusions Tivozanib significantly improves PFS and ORR compared to sorafenib in patients with treatment-refractory advanced RCC Tivozanib was superior in patients previously treated with checkpoint inhibitors as well as two VEGFR-TKIs Responses with tivozanib were more durable than sorafeni
Slide 16: PD-1 Combination Opportunities
PD-1 Combination Opportunities
Slide 17: Tivozanib Properties May Provide Advantages in Combination with IO Therapy
Tivozanib Properties May Provide Advantages in Combination with IO Therapy Nakamura K et al. Cancer Res 2006;66:9134–9142. Pawlowski N et al. AACR 2013. Poster 3971. Hammers, Emerging VEGF-I/O Combinations, ASCO 2017
Slide 18: TiNivo Phase 1/2 Data Presented at ESMO 2019
Phase 2 Data Presented at ESMO in September 2019 Tivozanib (1.0 mg/day) QD/21 days + nivolumab 240 mg Q2 weeks N = 6 ECOG PS ≤ 1 and life expectancy ≥ 3 months Tivozanib (1.5 mg/day) QD/21 days + nivolumab 240 mg Q2 weeks Tivozanib (1.5 mg/day) QD/21 days + nivolumab 240mg Q2 weeks Phase 1 Phase 2 N
Slide 19: ESMO 2019: Encouraging Safety Results
ESMO 2019: Encouraging Safety Results Hypertension (52%) is the most common grade 3/4 AE Only 17% of patients required a dose reduction Barthelemy et al. ESMO 2019
Slide 20: ESMO 2019: Encouraging Efficacy
ESMO 2019: Encouraging Efficacy 56% ORR and 96% DCR 72% had tumor shrinkage ≥ 25% 4% of patients had a complete response mPFS of 18.9 months Results suggest additive or synergistic efficacy for tivozanib + PD-1 Barthelemy et al. ESMO 2019
Slide 21: Combination of PD-1 + VEGF TKIs: Promising Responses
Combination of PD-1 + VEGF TKIs: Promising Responses, All Phase 3 Currently 1st Line Efficacy N (%) Tivozanib + Nivolumab1 Total N=25 Pembro + Lenvatinib2 Total N=30 Cabo + Nivo or IpiNivo3 Total N=13 Axitinib + Pembro4 Total N=52 Axitinib + Avel5 Phase 3 Total N=442 (ITT) Axitinib + Pembro6 Total N
Slide 22: TiNivo – Strong Efficacy in Treatment Naive and Previously Treated Patients
TiNivo – Strong Efficacy Seen in Both Treatment Naive and Previously Treated Patients Treatment Naïve (12) Pre-Treated (13*) Overall (25) CR 8% - 4% PR 42% 62% 52% SD 42% 38% 40% PD 8% - 4% ORR (CR+PR) 50% 62% 56% DCR (CR+PR+SD) 92% 100% 96% mPFS 18.9 mo (4.7, NR) NR (11.0, NR) 18.9 mo (16.4, NR) TX
Slide 23: Immuno-Oncology Clinical Collaboration with AstraZeneca
Immuno-Oncology Clinical Collaboration with AstraZeneca Clinical Rationale: Single agent activity demonstrated for tivozanib and durvalumab in HCC2,3. Combination of two agents has potential to show enhanced efficacy and tolerability profile among TKI/IO regimens. Planned Phase 1/2 study: Costs shar
Slide 24: Tivozanib Commercial Opportunity
Tivozanib Commercial Opportunity
Slide 25: Significant Potential Commercial Opportunity for Tivozanib in the United States
If Approved, Significant Potential Commercial Opportunity for Tivozanib in the United States 1st Line Market (est. 2020) ~$1.6B1 2nd Line Market (est. 2020) ~$700M1 3rd Line+ Market (est. 2020) ~$300M1 Expect opportunity to expand Potential to be first agent indicated for 3rd & 4th line Only pivotal
Slide 26: Potential Relevance of Tivozanib in Refractory RCC
Potential Relevance of Tivozanib in Refractory RCC Source: AVEO blinded Third-Party U.S. Oncologist Market Research using approximate TIVO-3 PFS and AE profile - Dec 2018 n=100 Treatments with proven efficacy are needed for patients who have failed 2 or more lines of treatment for RCC I prefer using
Slide 27: FOTIVDA Commercialization in EU and ROW
First-line treatment for patients with good or intermediate risk Second-line patients following TKIs Launched in Germany, Spain and UK Approved in New Zealand https://www.esmo.org/Guidelines/Genitourinary-Cancers/Renal-Cell-Carcinoma FOTIVDA® Commercialization in EU and ROW This Photo by Unknown Aut
Slide 28: Pipeline and Near-Term Milestones
Pipeline and Near-Term Milestones
Slide 29: Tivozanib
Tivozanib * Does not include potential PTE up to 5 yr max VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor Launched in Europe by EUSA as FOTIVDA® in first line RCC in November 2017 TIVO-3 study on-going for potential U.S. registration for RCC Tivozanib + OPDIVO® Phase 1/2 in collaboration with BMS complet
Slide 30: Ficlatuzumab
Ficlatuzumab * Does not include potential PTE up to 5 yr max HGF Inhibitory Antibody with Optimal Blockade of c-Met AML: Phase 1/2 trial of ficlatuzumab and cytarabine in refractory AML patients (n=18) Demonstrated 50% CR in patients refractory to initial therapy Randomized Phase 2 in planning SCCHN
Slide 31: CAN017 (AV-203): Anti-ERBB3 MAb with Broad Therapeutic Potential
Anti-ERBB3 Mab with Broad Therapeutic Potential CANbridge to fund clinical development through Phase 2 POC study Potential additional $40.0M development and regulatory/$90.0M commercial milestone Tiered low double-digit royalties for ex-NA rights Planned indication: squamous cell esophageal cancer (
Slide 32: AV-380: First-in-Class Anti-GDF15 MAb for Cachexia
First-in-Class, Anti-GDF15 MAb for Cachexia Cachexia affects approximately 5 million patients in the U.S. alone; affects up to 80% of advanced cancer patients and is responsible for approximately 30% of all cancer deaths1,2 Pre-clinical development underway to enable planned IND submission in 2020 C
Slide 33: AVEO Key Near Term Potential Milestones
AVEO Key Near Term Potential Milestones Tivozanib (VEGFR 1, 2 and 3 TKI) 2H19 1H20 2H20 TIVO-3 OS Update / Regulatory Discussion DEDUCTIVE HCC Ph 1/2 (Durvalumab + Tivo) Initiation TiNivo RCC (Nivolumab + Tivo) Final PFS Presentation Ficlatuzumab (HGF Inhibitory Antibody) 2H19 1H20 2H20 AML Randomiz
Slide 34: AVEO Overview October 2019
AVEO Overview October 2019
AVEO Pharmaceuticals — Investor Presentation (October 2019) on 6ix